A Critical Role for Glycine Transporters in Hyperexcitability Disorders by Harvey, Robert J. et al.
March 2008  |  Volume 1  |  Article 1  |  www.frontiersin.org
1
A critical role for glycine transporters in hyperexcitability 
disorders
Robert J. Harvey1,*, Eloisa Carta1, Brian R. Pearce1, Seo-Kyung Chung2, Stéphane Supplisson3, 
Mark I. Rees2,4 and Kirsten Harvey1
1. Department of Pharmacology, The School of Pharmacy, London, UK
2. Institute of Life Science, School of Medicine, Swansea University, Swansea, UK
3. Laboratoire de Neurobiologie, CNRS, Ecole Normale Supérieure, Paris, France
4. Institute of Medical Genetics, School of Medicine, Cardiff University, Wales, UK
Edited by:  Jochen C. Meier, Max Delbrück Center for Molecular Medicine, Germany
Reviewed by:  Jean-Marc Fritschy, University of Zurich, Switzerland
Defects in mammalian glycinergic neurotransmission result in a complex motor disorder characterized by neonatal hypertonia and 
an exaggerated startle reﬂ  ex, known as hyperekplexia (OMIM 149400). This affects newborn children and is characterized by noise 
or touch-induced seizures that result in muscle stiffness and breath-holding episodes. Although rare, this disorder can have serious 
consequences, including brain damage and/or sudden infant death. The primary cause of hyperekplexia is missense and non-
sense mutations in the glycine receptor (GlyR) α1 subunit gene (GLRA1) on chromosome 5q33.1, although we have also discovered 
rare mutations in the genes encoding the GlyR β subunit (GLRB) and the GlyR clustering proteins gephyrin (GPNH) and collybistin 
(ARHGEF9). Recent studies of the Na+/Cl−-dependent glycine transporters GlyT1 and GlyT2 using mouse knockout models and human 
genetics have revealed that mutations in GlyT2 are a second major cause of hyperekplexia, while the phenotype of the GlyT1 knockout 
mouse resembles a devastating neurological disorder known as glycine encephalopathy (OMIM 605899). These ﬁ  ndings highlight the 
importance of these transporters in regulating the levels of synaptic glycine.
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INTRODUCTION
We have employed an alternative approach to the study of inhibitory 
synapses, integrating data from mouse models and proteomic studies 
to identify biologically plausible candidate genes for genetic analysis in 
human neurological disorders. This approach has resulted in the identi-
ﬁ  cation of mutations in the genes for the GlyR α1 and β subunits (Rees 
et al., 1994, 2001, 2002), gephyrin (Rees et al., 2003) and the RhoGEF 
collybistin (Harvey et al., 2004), all postsynaptic proteins found at inhibi-
tory synapses (Figure 1). However, the relative dearth of remaining well-
characterized postsynaptic targets, taken together with new phenotypic 
data from glycine transporter (GlyT) knockout models (Gomeza et al., 
2003a,b) have resulted in a shift of focus towards presynaptic and glial 
mechanisms of disease.
Mutations in the GlyT2 gene (SLC6A5) deﬁ  ne a presynaptic 
component of hyperekplexia
Mouse models of GlyR dysfunction, such as spastic,  spasmodic and 
oscillator have traditionally served as excellent leads for genetic analysis 
of the corresponding genes in human neurological illness, in particular 
 hyperekplexia  (Buckwalter et al., 1994; Kingsmore et al., 1994; Kling 
et al., 1997; Mulhardt et al., 1994; Ryan et al., 1994; Saul et al., 1994). 
For this reason, it was of interest that Gomeza et al. (2003b) reported 
that the phenotype of knockout mice for the presynaptic glycine trans-
porter GlyT2 also resembled human hyperekplexia. GlyT2 knockout mice 
gain weight slowly and die prematurely at the end of the second postna-
tal week, displaying a complex neurological phenotype characterized by 
spasticity, rigid muscle tone, strong spontaneous tremor and a severely 
impaired righting reﬂ  ex (Gomeza et al., 2003b). GlyTs are members of the 
neurotransmitter transporter superfamily (Betz et al., 2006; Eulenburg 
et al., 2005; Supplisson and Roux, 2002), integral membrane proteins 
that utilize Na+ and Cl− electrochemical gradients to recapture neuro-
transmitters at central synapses. This superfamily includes four sub-
families of transporters for biogenic amines (norepinephrine, dopamine, 
serotonin), GABA and osmolytes (betaine, taurine, creatine), amino acids 
  (glycine, proline) as well as several ‘orphan’ transporters (Broer, 2006). 
GlyTs have dual functions at both inhibitory and excitatory synapses, 
resulting from the differential localisation of two distinct transporters, 
GlyT1 and GlyT2. GlyT1 is expressed in astroglial cells, exhibits a 2 Na+/1 
Cl−/1 glycine stoichiometry and bi-directional glycine transport (Jursky 
and Nelson, 1995, 1996; Roux and Supplisson, 2000). These properties 
are appropriate for the control of extracellular glycine concentrations 
in the submicromolar range for modulation of excitatory N-methyl-D-
aspartate (NMDA)   selective glutamate receptors (Gabernet et al., 2005; 
Martina et al., 2005; Singer et al., 2007; Tsai et al., 2004; Yee et al., 
2006), where glycine acts as a co-agonist, and also for terminating neu-
rotransmission at inhibitory glycinergic synapses (Gomeza et al., 2003a). 
By contrast, GlyT2 is found in glycinergic axons, exhibits a 3 Na+/1 Cl−/1 
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glycine stoichiometry and does not display reverse uptake (Roux and 
Supplisson, 2000). These peculiar properties reﬂ  ect an   essential role 
for GlyT2 in   maintaining a high presynaptic pool of neurotransmitter 
at glycinergic synapses (Figure 1). To assess whether mutations in the 
human GlyT2 gene could cause hyperekplexia, we scanned all 16 coding 
exons of the SLC6A5 gene (11p15.1) by dHPLC analysis in an interna-
tional cohort of 83   sporadic and familial hyperekplexia patients devoid 
of mutations in GLRA1, GLRB, GPHN and ARHGEF9. Direct sequencing of 
aberrant dHPLC   proﬁ  les revealed a mosaic of missense and nonsense 
mutations in SLC6A5 ( Figure 2) and additional regions of high-fre-
quency SNPs (Rees et al., 2006). In the majority of cases, GlyT2 muta-
tions were inherited as compound heterozygotes indicating that SLC6A5 
is predominantly associated with recessive hyperekplexia, although one 
dominant mutation was identiﬁ  ed. Subcellular localisation studies using 
EGFP-tagged wild-type and mutant GlyT2 proteins, [3H]-glycine uptake 
assays and voltage-clamp   electrophysiological analysis in Xenopus 
oocytes revealed that GlyT2 mutations result in defective subcellular 
localisation and/or decreased glycine uptake, with selected mutations 
affecting glycine and Na+ binding to the transporter (Rees et al., 2006). 
Insights into the precise molecular mechanisms underlying GlyT2 mis-
sense mutations were provided using the high resolution structure of the 
bacterial leucine transporter (LeuT) (Yamashita et al., 2005). Alignments 
of GlyT2 and LeuT revealed that mutations that disrupt glycine or Na+ 
binding to GlyT2 were predicted to form part of equivalent leucine or 
Na+ binding sites on LeuT (Figure 2). These results demonstrated that 
SLC6A5 was a major gene for hyperekplexia and deﬁ  ned the ﬁ  rst neuro-
logical disorder linked to mutations in a Na+/Cl−-dependent transporter 
for a classical fast neurotransmitter. It is also of interest to note that 
GlyT2 mutations are not lethal in humans: although patients harbouring 
mutations in SLC6A5 presented with   hypertonia, an exaggerated star-
tle response to tactile or acoustic stimuli and life-threatening neonatal 
apnoea episodes, in most cases these   symptoms resolved in the ﬁ  rst 
year of life following intensive postnatal and infant care. This may reﬂ  ect 
a stronger contribution of GABAergic vs. glycinergic signalling in humans 
in postnatal development.
GlyT2 interacting proteins and VIAAT as candidate genes for further 
genetic analysis in hyperekplexia
Despite signiﬁ  cant advances in the genetics of hyperekplexia, our cohort 
still contains ~60 single, unrelated, sporadic cases of hyperekplexia 
which are gene-negative for mutations in GLRA1,  GLRB,  ARHGEF9, 
GPHN and SLC6A5. This suggests that further hyperekplexia genes 
remain undiscovered, and underlines the genetic heterogeneity asso-
ciated with this disorder. Further presynaptic candidates for possible 
genetic analysis include the vesicular inhibitory amino acid transporter 
(VIAAT) and the GlyT2 accessory proteins syntenin-1 and ULIP6. ULIP6 is 
encoded by DPYSL5 (2p23.3) and is a brain-speciﬁ  c phosphoprotein of 
the Ulip/  collapsin response mediator protein family. ULIP6 interacts with 
amino acids 135–184 of the GlyT2 N-terminal intracellular domain in a 
  phosphorylation-dependent manner (Horiuchi et al., 2005). The associa-
tion of ULIP6 with GlyT2 is relatively speciﬁ  c, since other members of this 
gene family (ULIP1-5) do not interact with GlyT2. Since ULIP6 has been 
implicated in GlyT2 endocytosis and recycling (Eulenburg et al., 2005; 
Horiuchi et al., 2005), it is possible that mutations in ULIP6 could cause 
hyperekplexia by altering steady-state levels of presynaptic GlyT2. By con-
trast, the PDZ containing protein syntenin-1, encoded by the gene SDCBP 
(8q12.1) is thought to regulate the trafﬁ  cking or presynaptic localisation 
of GlyT2 in glycinergic neurones (Ohno et al., 2004). Although syntenin-1 
and GlyT2 show extensive co-localisation in brainstem sections, syntenin-
1 has numerous binding partners (Hirbec et al., 2002, 2005), including 
AMPA, kainate and metabotropic glutamate receptors,   syndecans, neu-
rexins and ephrin B, so any mutations in this protein might be expected 
to have diverse effects. Another plausible hyperekplexia candidate is 
VIIAT (Chaudry et al., 1998; McIntire et al., 1997; Sagné et al., 1997), 
Figure 1.  A model showing key proteins at mature glycinergic synapses. Postsynaptic α1β subunit GlyRs are clustered by gephyrin. Although the RhoGEF 
  collybistin is responsible for the translocation of gephyrin to GABAergic synapses (Harvey et al., 2004; Papadopoulos et al., 2007), collybistin may be dispensa-
ble for GlyR clustering, since collybistin knockout mice do not exhibit developmental onset of exaggerated acoustic or tactile startle responses (Papadopoulos 
et al., 2007). This suggests that additional RhoGEFs involved in the synaptic localisation of gephyrin and inhibitory receptors remain to be identiﬁ  ed. The glial 
glycine transporter GlyT1 removes glycine from the synaptic cleft, thereby terminating neurotransmission. By contrast, GlyT2 (which binds ULIP6 and syntenin-1) 
is responsible for glycine re-uptake into the nerve terminal cytosol. This in turn provides glycine for the vesicular transporter VIAAT to reﬁ  ll synaptic vesicles. 
Glycine is also synthesised by a de novo pathway involving serine hydroxymethyl transferase (SHMT). Loss of glial GlyT1 uptake may cause raised CSF and 
serum glycine, leading to glycine encephalopathy.Genetic defects in glycine transporters
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Figure 2. Amino acid sequence of human GlyT1 and GlyT2 indicating the revised positions of putative transmembrane (TM) domains (coloured 
boxes) based on the structure of the bacterial leucine transporter (LeuT) (Yamashita et al., 2005). Mutations identiﬁ  ed in human GlyT2 in hyperekplexia 
(Rees et al., 2006) are indicated by black boxes. Blue triangles above the sequence indicate residues in hGlyT1 and hGlyT2 that are likely to coordinate Na+ ions 
based on sequence alignments with the bacterial LeuT (Yamashita et al., 2005). However, it is noteworthy that GlyT2 binds three Na+ ions, while LeuT and GlyT1 
bind two, suggesting that other residues involved in Na+ co-ordination remain to be identiﬁ  ed in GlyT2. Filled black circles above the sequences indicate residues 
predicted to be involved in glycine binding. Note that mutations W482R and N509S alter putative glycine and Na+ binding residues, respectively.
encoded by the gene SLC32A1 on human   chromosome 20q11.23. VIAAT 
is a transporter present in both GABAergic and glycinergic neurones 
(Chaudry et al., 1998), and is responsible for the loading of presynaptic 
vesicles with glycine and GABA. Although a recent knockout mouse for 
VIAAT has shown a severe phenotype (embryonic lethality, omphalocele 
and cleft palate) (Wojcik et al., 2006), it remains possible that missense 
mutations in VIAAT could lead to the loss of either GABA or glycine load-
ing into synaptic vesicles. VIAAT was ﬁ  rst identiﬁ  ed (McIntire et al., 1997) Harvey et al.
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as a mammalian homologue of the ‘uncoordinated’ C. elegans mutant 
unc-47, which was known to be defective in a presynaptic component of 
GABA release. Three mutations in unc-47 were characterized by McIntire 
et al. (1997): (1) a G to A transition affecting a splice acceptor site, (2) a 
238-bp deletion that removes part of the coding region and (3) a G to A 
transition causing the substitution G462R. Despite the fact that C. elegans 
does not appear to use glycine as a neuro  transmitter (Schuske et al., 
2004), using a sophisticated cellular assay, Aubrey et al. (2007) were able 
to demonstrate that UNC-47 is able to transport both GABA and glycine 
into vesicles. However, mutation G462R abolishes GABA, but not gly-
cine uptake. Since residue G462 is conserved at the equivalent position 
(G500) in rodent and human VIAAT sequences, mutations in SLC32A1 
could compromise GABA uptake into synaptic vesicles while leaving gly-
cine uptake intact. Since similar mutations could affect glycine uptake, 
leaving GABA transport intact, missense mutations in SLC32A1 could 
potentially cause hyperekplexia.
Disruption of the mouse GlyT1 gene: 
a mouse model of glycine encephalopathy
Knockout mouse models of GlyT1 dysfunction (Gomeza et al., 2003a) 
have suggested the intriguing possibility that mutations in the corre-
sponding gene in humans (SLC6A9) could cause glycine encephalopathy 
(OMIM 605899), also known as non-ketotic hyperglycinemia (Applegarth 
and Toone, 2006). Homozygous GlyT1 knockout mice exhibit severe 
motor deﬁ  cits accompanied by lethargy, hypotonia and   hyporesponsivity, 
and die within 6–14 hours after birth as a result of respiratory failure, 
although wasting and dehydration caused by an inability to suckle may 
also play a role (Gomeza et al., 2003a; Tsai et al., 2004). In a series of 
elegant experiments, Gomeza et al. (2003a) demonstrated  that this phe-
notype was not due to increased NMDA receptor activity, but rather that 
glial glycine clearance at glycinergic synapses was compromised in GlyT1 
knockouts. GlyT1 deﬁ  cient mice displayed increased chloride conduct-
ance at brainstem synapses, consistent with a tonic activation of GlyRs 
by elevated glycine concentrations. Furthermore, spontaneous inhibitory 
postsynaptic currents had longer decay time constants than those in 
wild-type littermates. Potentiation of inhibitory glycinergic transmission 
is also observed in the zebraﬁ  sh mutant shocked, where a missense 
mutation causing a G81D substitution in TM2 disrupts GlyT1 function, 
causing motor deﬁ  cits such as reduced spontaneous coiling of the trunk, 
diminished escape responses when touched, and an absence of swim-
ming (Cui et al., 2005). These observations suggest that GlyT1 plays a 
fundamental role in terminating glycinergic transmission by removing 
glycine from the synaptic cleft (Cui et al., 2005; Gomeza et al., 2003a). 
Potentiation of glycinergic neurotransmission is likely to be responsible 
for the early postnatal death of GlyT1 knockout mice, since recordings 
of neuronal activity in the brain stem circuitry responsible for generat-
ing the respiratory rhythm disclosed a slowed and irregular breathing 
pattern, which could be normalized by the GlyR antagonist strychnine 
(Gomeza et al., 2003a). Antagonism of exaggerated glycinergic neuro-
transmission by strychnine also restored spontaneous coiling and swim-
ming behaviours in zebraﬁ  sh shocked mutants (Cui et al., 2005).
Gomeza et al. (2003a) also speculated that the overall reduction of 
motosensory functions in GlyT1 knockout mice was similar to symp-
toms of glycine encephalopathy in humans, a disease associated with 
 disruption of the mitochondrial glycine cleavage system, which degrades 
excess   glycine (Applegarth and Toone, 2006; Sakata et al., 2001). In 
  typical cases with early neonatal onset, convulsive seizures, coma or 
respiratory distress develop within a few days after birth. One third of 
patients die within the ﬁ  rst year of life, many in the neonatal period, 
often of respiratory impairment which can be treated with appropriate 
support. Those who survive can live for many years, but suffer varying 
degrees of mental retardation, having an average developmental age of 
between 3–6 months, as well as intractable seizures (Applegarth and 
Toone, 2006; Conter et al., 2006; Sakata et al., 2001). Conﬁ  rmation of 
diagnosis requires: (1) detection of raised cerebrospinal ﬂ  uid (CSF) and 
plasma glycine concentrations and exclusion of organic acid disease 
by urinary organic acid assay; (2) a biochemical assay revealing a dis-
rupted glycine cleavage enzyme complex in liver and (3) identiﬁ  cation of 
mutations in one of the four genes of the mitochondrial glycine cleavage 
enzyme complex, encoding the P-protein (a pyridoxyl-dependent glycine 
decarboxylase, GLDC), the H-protein (a lipoic acid-containing hydrogen 
carrier protein), the T protein (a tetrahydrofolate-dependent aminometh-
yltransferase) and the L protein (lipoamide dehydrogenase). Mutations in 
the P-, H- and T-proteins have been identiﬁ  ed in glycine encephalopathy 
(Applegarth and Toone, 2006; Conter et al., 2006; Sakata et al., 2001). 
More than 80% of patients have a defect in the P-protein gene (GLDC, 
9p24.1), while 15% of patients have defects in the T-protein gene (AMT, 
3p21.31). Defects in the H-protein gene (GCSH, 16q23.2) are extremely 
rare. However, there are also reports of individuals with glycine enceph-
alopathy who have normal GCS activity in liver and brain, but defec-
tive CNS glycine transport in postmortem tissue (Applegarth and Toone, 
2006; Mayor et al., 1985). We consider that mutations in the human 
GlyT1 gene (SLC6A9; 1p34.1) could underlie glycine encephalopathy in 
these cases, since the loss of glial GlyT1 uptake would be expected to 
raise CSF glycine, while loss of GlyT1 from peripheral sites, including 
the liver (Jursky and Nelson, 1996) (Figure 3) could also lead to raised 
serum glycine. The activity of the isolated glycine cleavage enzyme com-
plex would not be affected, since this complex is assayed in a cell-free 
lysate isolated from liver biopsy, and would therefore be independent of 
GlyT1 function. However, it has not yet been demonstrated that GlyT1 
knockout mice actually have the main features expected of a mouse 
model of glycine encephalopathy, i.e., raised CSF and serum glycine in 
the presence of normal mitochondrial glycine cleavage enzyme complex 
activity (Applegarth and Toone, 2006). Such measurements might allow 
researchers to establish a biochemical ‘proﬁ  le’ of a human patient with 
mutations in the GlyT1 gene.
Modulation of excitatory glutamate receptor function by GlyT1
Knockout mice for GlyT1 have also underlined a key role for GlyTs in 
modulating excitatory NMDAR activity (Gabernet et al., 2005; Martina 
et  al., 2005; Singer et  al., 2007; Tsai et  al., 2004; Yee et  al., 2006). 
Historically, there have been reservations about the in vivo role of the NR1 
glycine co-agonist site of NMDARs (Johnson and Ascher, 1987) because 
Figure 3. Distribution of GlyT1 and GlyT2 in sections from mouse E18 
embryos. Note that GlyT2 immunoreactivity is mostly conﬁ  ned to spinal cord 
(Sc) and brainstem, while GlyT1 is also expressed in some higher brain regions 
and peripheral tissues, especially liver (L) and pancreas (P). Reproduced with 
permission from: F. Jursky and N. Nelson: Developmental expression of the gly-
cine transporters GlyT1 and GlyT2 in mouse brain. Journal of Neurochemistry 
67(1), 336–344 (1996), Wiley-Blackwell, Oxford, UK.Genetic defects in glycine transporters
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the average concentration of glycine in CSF was expected to be in low 
micromolar range, while the afﬁ  nity of glycine for the glycine modula-
tory site of the NMDAR ranges from 0.1 to 3 µM depending on the type 
of NR2 subunit present. Under these conditions, the NMDAR co-agonist 
site would always be fully saturated and therefore of no physiological 
or pharmacological relevance. Moreover, other studies have suggested 
that glial-derived D-serine, rather than glycine, is the endogenous lig-
and for the NMDAR co-agonist site (Mothet et al., 2000; Panatier et al., 
2006). However, the location of the glycine transporter GlyT1 on astroglia 
(Zafra et al., 1995) in close proximity to synaptic NMDARs could cause a 
localized reduction in glycine levels in the sub micromolar range (Berger 
et al., 1998; Supplisson and Bergman, 1997). More recently, GlyT1 has 
been localized to pre- and postsynaptic aspects of glutamatergic syn-
apses, particularly in the neocortex and hippocampus (Cubelos et al., 
2005a) and have been shown to interact (Cubelos et al., 2005b) with 
PDZ domains I and II of PSD-95, a scaffolding protein that also binds 
to NMDARs. Interestingly, the GlyT1-PSD95 interaction stabilises the 
transporter at the plasma membrane and produces a signiﬁ  cant increase 
in the Vmax of glycine uptake (Cubelos et al., 2005b). Studies of GlyT1 
modulation of NMDAR function are slightly complicated by the fact that 
homozygous GlyT1 knockout mice die soon after birth. However, experi-
ments using heterozygous GlyT1 mice (GlyT1+/−) or tissue-speciﬁ   c 
GlyT1 knockouts have been more illuminating. Unlike homozygous GlyT1 
knockout mice, heterozygous GlyT1 mice are phenotypically normal, but 
have a demonstrable loss of [3H]glycine uptake in brain homogenates 
compared to wild-type mice (Gomeza et al., 2003a; Tsai et al., 2004). 
Heterozygous GlyT1 mice exhibit an enhanced NMDA/AMPA response 
ratio, suggesting that increased glycine levels lead to major functional 
changes at glutamatergic synapses (Gabernet et al., 2005; Martina et al., 
2005; Tsai et al., 2004). In addition, GlyT1+/− mice show resistance to 
pharmacological disruption of prepulse inhibition (PPI) by amphetamine 
(Tsai et al., 2004). PPI is a neurological phenomenon in which a weaker 
prestimulus (prepulse) inhibits the reaction of an organism to a subse-
quent strong startling stimulus (pulse). Deﬁ  cits of PPI manifest in the 
inability to ﬁ  lter out the unnecessary information and have been linked to 
abnormalities of   sensorimotor gating such as those observed in schizo-
phrenia. Lastly, GlyT1+/− mice show improved spatial memory reten-
tion (Tsai et al., 2004), while selective disruption of GlyT1 in forebrain 
neurones results in enhanced associative and object recognition memory 
(Singer et al., 2007; Yee et al., 2006). Taken together, these studies sug-
gest that reduced expression of GlyT1 enhances memory retention, and 
protects against disruptions of sensory gating, suggesting that GlyT1 
may represent a target for novel cognition-enhancing and antipsychotic 
drugs.
DISCUSSION AND PERSPECTIVES
The study of existing and newly characterized GlyT2 hyperekplexia 
mutations is expected to reveal important residues and domains of inter-
est that will inﬂ  uence structure/function studies on other members of 
the Na+/Cl−-dependent transporter superfamily. Screening of the genes 
encoding ULIP-6, syntenin-1 and VIAAT in individuals with hyperekplexia 
may reveal additional presynaptic disease genes, and provide a solu-
tion for those families awaiting a deﬁ  nitive genetic diagnosis. GlyT1 
knockout mice will also be instrumental in establishing a ‘patient proﬁ  le’ 
for   possible human glycine encephalopathy cases involving mutations 
in the GlyT1 gene. Screening of individuals with glycine encephalopa-
thy that do not have obvious glycine cleavage system deﬁ  ciencies will 
reveal whether GlyT1 has a role in this devastating postnatal neurologi-
cal disorder.
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